Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52 percent PSA50 and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments

AMAMDelisted Stock  USD 15.73  0.71  4.73%   
About 55% of Ambrx Biopharma's investors are presently thinking to get in. The analysis of current outlook of investing in Ambrx Biopharma American suggests that some traders are interested regarding Ambrx Biopharma's prospects. Ambrx Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in Ambrx Biopharma American. Many technical investors use Ambrx Biopharma American stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Newly published data from the Phase 1 portion of the on-goingPhase 1 2 APEX-01 trial provide the following key points Multiple efficacy endpoints demonstrate consistent and promising anti-cancer activity at

Read at benzinga.com
benzinga news
  

Ambrx Biopharma Fundamental Analysis

We analyze Ambrx Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ambrx Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ambrx Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Target Price

Target Price Comparative Analysis

Ambrx Biopharma is currently under evaluation in target price category among its peers.

Ambrx Biopharma American Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ambrx Biopharma stock to make a market-neutral strategy. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics with similar companies.

Peers

Ambrx Biopharma Related Equities

XFORX4 Pharmaceuticals   11.43   
0%
100.0%
IMMXImmix Biopharma   7.11   
0%
62.0%
HEPAHepion Pharmaceuticals   4.69   
0%
41.0%
ELEVElevation Oncology   3.23   
0%
28.0%
ENVBEnveric Biosciences   3.13   
0%
27.0%
ZURAZura Bio   1.67   
0%
14.0%
DAWNDay One   1.53   
0%
13.0%
ABOSAcumen Pharmaceuticals   0.44   
0%
3.0%
INZYInozyme Pharma   0.37   
3.0%
0%
OCEAOcean Biomedical   1.41   
12.0%
0%
SONNSonnet Biotherapeutics   2.28   
19.0%
0%
CNSPCns Pharmaceuticals   8.33   
72.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Consideration for investing in Ambrx Stock

If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios